NAFDAC Alerts Public On Sale Of Counterfeit Noristerat Injection 200mg In Nigeria

The National Agency for Food and Drug Administration and Control (NAFDAC) has alerted the public about the sale of Chlorpheniramine and Dexamethasone injection ampoules that are mislabelled and repacked as Noristerat Injection 200mg.

NAFDAC said this in an official statement on Monday.

Samples of the counterfeit product have been reported to be found in Niger State, Bauchi State, and especially the Coordinated Wholesale Centre (CWC) in Kano state.

ALSO READ: Fubara To Bloggers: Don’t Destabilise Rivers With Your Posts

NAFDAC added: “It is important to note that the counterfeiter has been tracked and arrested for further investigation and enforcement of regulatory sanctions.

“Genuine Noristerat 200mg is a contraceptive injection that offers 8 weeks of pregnancy protection. It is a short-term birth control method.”

Product details
The details of the falsified Noristerat 200mg injection are as follows.

Details of the counterfeit product are as follows:

Product Details

Counterfeit

Product Name

Noristerat Injection

Stated NRN

04-5715

Manufacturing Date

09/22

Expiring Date

09/27

Lot. No

KT02TTK

Product photo

“All NAFDAC zonal directors and state coordinators have been directed to carry out surveillance and mop up the falsified product within the zones and states.

“Importers, distributors, retailers, healthcare professionals, and caregivers are advised to exercise caution and vigilance in the supply chain to prevent the importation, distribution, sale, and use of falsified products. All medical products must be obtained from authorized/licensed suppliers. The products’ authenticity and physical condition should be carefully checked.

“Healthcare professionals and consumers are advised to report any suspicion of sale of substandard and falsified medicines or medical devices to the nearest NAFDAC office, NAFDAC on 0800-162-3322 or via email: [email protected]

“Similarly, healthcare professionals and patients are also encouraged to report adverse events or side effects related to the use of medicinal products or devices to the nearest NAFDAC office, or through the use of the E-reporting platforms available on the NAFDAC website www.nafdac.gov.ng or via the Med- safety application available for download on android and IOS stores or via e-mail on [email protected],” the agency said.

“Furthermore, note that this notice will be uploaded to the WHO Global Surveillance and Monitoring System (GSMS),” the statement concluded.